Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $14.00.

KLRS has been the topic of several recent research reports. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Finally, Chardan Capital initiated coverage on Kalaris Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 target price on the stock.

Kalaris Therapeutics Stock Up 2.8%

Kalaris Therapeutics stock opened at $5.93 on Thursday. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $11.88. The company has a market cap of $135.97 million, a P/E ratio of -1.41 and a beta of 0.18. The business has a 50-day simple moving average of $8.78 and a two-hundred day simple moving average of $7.40.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.12.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kalaris Therapeutics during the 4th quarter valued at approximately $34,000. Barclays PLC bought a new stake in Kalaris Therapeutics during the 4th quarter worth approximately $51,000. Johnson Financial Group Inc. purchased a new position in Kalaris Therapeutics during the third quarter valued at approximately $58,000. Keel Point LLC purchased a new position in Kalaris Therapeutics during the fourth quarter valued at approximately $86,000. Finally, XTX Topco Ltd bought a new position in shares of Kalaris Therapeutics in the fourth quarter worth approximately $92,000. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.